A UK patient’s HIV has become “undetectable” following a stem cell transplant – in only the second case of its kind, doctors report in Nature.
The London patient, who was being treated for cancer, has now been in remission from HIV for 18 months and is no longer taking HIV drugs.
The researchers say it is too early to say the patient is “cured” of HIV.
Experts say the approach is not practical for treating most people with HIV but may one day help find a cure.
The male London patient, who has not been named, was diagnosed with HIV in 2003 and advanced Hodgkin’s lymphoma in 2012.
He had chemotherapy to treat the Hodgkin’s cancer and, in addition, stem cells were implanted into the patient from a donor resistant to HIV, leading to both his cancer and HIV going into remission.
Researchers from University College London, Imperial College London, Cambridge and Oxford Universities were all involved in the case.
‘Not an anomaly’
This is the second time a patient treated this way has ended up in remission from HIV.
Ten years ago, another patient in Berlin received a bone-marrow transplant from a donor with natural immunity to the virus.
Timothy Brown, said to be the first person to “beat” HIV/Aids, was given two transplants and total body irradiation (radiotherapy) for leukaemia – a much more aggressive treatment.
“By achieving remission in a second patient using a similar approach, we have shown that the Berlin patient was not an anomaly and that it really was the treatment approaches that eliminated HIV in these two people,” said lead study author Prof Ravindra Gupta, from UCL.
Hope of a cure?
Although the finding is exciting, it is not offering up a new treatment for the millions of people around the world living with HIV.
The aggressive therapy was primarily used to treat the patient’s cancer, not his HIV.
Current HIV therapies are really effective, meaning people with the virus can live long and healthy lives.
But the reason this case is so significant is that it could help experts who are looking for new ways to tackle HIV and achieve a cure.
But he added: “The treatment is not appropriate as a standard HIV treatment because of the toxicity of chemotherapy, which in this case was required to treat the lymphoma.”
Image copyright Getty Images
Dr Andrew Freedman, reader in infectious diseases and honorary consultant physician at Cardiff University, said it was an “interesting and potentially significant report”.
But he said much longer follow-up would be needed to ensure the virus did not re-emerge at a later stage.
In the meantime, he said the focus needed to be on diagnosing HIV promptly and starting patients on lifelong combination antiretroviral therapy (cART).
This can prevent the virus being transmitted to others and give people with HIV a near-normal life expectancy.